AI drug developers Recursion, Exscientia to merge

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company.

The new company will continue using the Recursion name and be led by Recursion co-founder and CEO Chris Gibson. Exscientia’s interim CEO, David Hallett, will serve as the company’s science chief. Recursion is spending $688 million in the all-stock deal, Reuters reported.

Recursion shareholders will own approximately 74% of the combined company and Exscientia shareholders will own approximately 26%.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase – Pharmaceutical Technology

Share this article Alpine’s lead asset is povetacicept being developed for renal indications and autoimmune cytopenias. Image credit: Shutterstock/Tada Images. Vertex Pharmaceuticals has agreed to

April 11, 2024

New prognostic marker identified for gastric cancer recurrence risk

Surgical removal of the tumor is considered the basis for curing gastric cancer. However, 40 per cent of patients who have undergone surgery suffer a

July 30, 2024

Expert consensus on the classification of acute atherothrombotic myocardial infarction by stage of tissue injury severity

A document published in the Canadian Journal of Cardiology outlines the Canadian Cardiovascular Society’s classification of acute MI.

November 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.